vs
Paylocity Holding Corp（PCTY）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Paylocity Holding Corp的2.0倍（$772.1M vs $387.0M），Paylocity Holding Corp净利率更高（13.0% vs 12.7%，领先0.2%），Paylocity Holding Corp同比增速更快（11.3% vs 5.9%），Revvity自由现金流更多（$161.8M vs $113.6M），过去两年Revvity的营收复合增速更高（9.0% vs 2.7%）
Paylocity Holding Corp是美国领先的云端人力资源管理服务商，核心产品覆盖薪资核算、支出管理及人力资本管理（HCM）类SaaS软件，可帮助不同规模的企业客户优化人力与财务相关运营流程，有效提升管理效率、降低运营成本。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
PCTY vs RVTY — 直观对比
营收规模更大
RVTY
是对方的2.0倍
$387.0M
营收增速更快
PCTY
高出5.4%
5.9%
净利率更高
PCTY
高出0.2%
12.7%
自由现金流更多
RVTY
多$48.2M
$113.6M
两年增速更快
RVTY
近两年复合增速
2.7%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $387.0M | $772.1M |
| 净利润 | $50.2M | $98.4M |
| 毛利率 | 72.9% | — |
| 营业利润率 | 18.2% | 14.5% |
| 净利率 | 13.0% | 12.7% |
| 营收同比 | 11.3% | 5.9% |
| 净利润同比 | 34.0% | 3.9% |
| 每股收益（稀释后） | $0.92 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PCTYRVTY
| Q4 25 | $387.0M | $772.1M | ||
| Q3 25 | $378.9M | $698.9M | ||
| Q2 25 | $369.9M | $720.3M | ||
| Q1 25 | $421.1M | $664.8M | ||
| Q4 24 | $347.7M | $729.4M | ||
| Q3 24 | $333.1M | $684.0M | ||
| Q2 24 | $324.7M | $691.7M | ||
| Q1 24 | $366.8M | $649.9M |
净利润PCTYRVTY
| Q4 25 | $50.2M | $98.4M | ||
| Q3 25 | $48.0M | $46.7M | ||
| Q2 25 | $48.6M | $53.9M | ||
| Q1 25 | $91.5M | $42.2M | ||
| Q4 24 | $37.5M | $94.6M | ||
| Q3 24 | $49.6M | $94.4M | ||
| Q2 24 | $48.8M | $55.4M | ||
| Q1 24 | $85.3M | $26.0M |
毛利率PCTYRVTY
| Q4 25 | 72.9% | — | ||
| Q3 25 | 73.9% | 53.6% | ||
| Q2 25 | 73.5% | 54.5% | ||
| Q1 25 | 77.1% | 56.5% | ||
| Q4 24 | 72.6% | — | ||
| Q3 24 | 74.4% | 56.3% | ||
| Q2 24 | 74.0% | 55.7% | ||
| Q1 24 | 77.8% | 54.6% |
营业利润率PCTYRVTY
| Q4 25 | 18.2% | 14.5% | ||
| Q3 25 | 19.6% | 11.7% | ||
| Q2 25 | 17.9% | 12.6% | ||
| Q1 25 | 30.2% | 10.9% | ||
| Q4 24 | 13.4% | 16.3% | ||
| Q3 24 | 19.3% | 14.3% | ||
| Q2 24 | 19.4% | 12.4% | ||
| Q1 24 | 29.0% | 6.8% |
净利率PCTYRVTY
| Q4 25 | 13.0% | 12.7% | ||
| Q3 25 | 12.7% | 6.7% | ||
| Q2 25 | 13.1% | 7.5% | ||
| Q1 25 | 21.7% | 6.4% | ||
| Q4 24 | 10.8% | 13.0% | ||
| Q3 24 | 14.9% | 13.8% | ||
| Q2 24 | 15.0% | 8.0% | ||
| Q1 24 | 23.3% | 4.0% |
每股收益（稀释后）PCTYRVTY
| Q4 25 | $0.92 | $0.86 | ||
| Q3 25 | $0.86 | $0.40 | ||
| Q2 25 | $0.87 | $0.46 | ||
| Q1 25 | $1.61 | $0.35 | ||
| Q4 24 | $0.66 | $0.77 | ||
| Q3 24 | $0.88 | $0.77 | ||
| Q2 24 | $0.85 | $0.45 | ||
| Q1 24 | $1.50 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $162.5M | $919.9M |
| 总债务越低越好 | $81.3M | — |
| 股东权益账面价值 | $1.1B | $7.3B |
| 总资产 | $7.0B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.07× | — |
8季度趋势，按日历期对齐
现金及短期投资PCTYRVTY
| Q4 25 | $162.5M | $919.9M | ||
| Q3 25 | $165.2M | $931.4M | ||
| Q2 25 | $398.1M | $991.8M | ||
| Q1 25 | $477.8M | $1.1B | ||
| Q4 24 | $482.4M | $1.2B | ||
| Q3 24 | $778.5M | $1.2B | ||
| Q2 24 | $401.8M | $2.0B | ||
| Q1 24 | $492.7M | $1.7B |
总债务PCTYRVTY
| Q4 25 | $81.3M | — | ||
| Q3 25 | $81.3M | — | ||
| Q2 25 | $162.5M | — | ||
| Q1 25 | $243.8M | — | ||
| Q4 24 | $325.0M | — | ||
| Q3 24 | $325.0M | — | ||
| Q2 24 | $0 | — | ||
| Q1 24 | — | — |
股东权益PCTYRVTY
| Q4 25 | $1.1B | $7.3B | ||
| Q3 25 | $1.1B | $7.4B | ||
| Q2 25 | $1.2B | $7.6B | ||
| Q1 25 | $1.2B | $7.6B | ||
| Q4 24 | $1.2B | $7.7B | ||
| Q3 24 | $1.1B | $7.9B | ||
| Q2 24 | $1.0B | $7.9B | ||
| Q1 24 | $1.1B | $7.8B |
总资产PCTYRVTY
| Q4 25 | $7.0B | $12.2B | ||
| Q3 25 | $4.2B | $12.1B | ||
| Q2 25 | $4.4B | $12.4B | ||
| Q1 25 | $5.2B | $12.4B | ||
| Q4 24 | $5.3B | $12.4B | ||
| Q3 24 | $4.0B | $12.8B | ||
| Q2 24 | $4.2B | $13.4B | ||
| Q1 24 | $5.0B | $13.4B |
负债/权益比PCTYRVTY
| Q4 25 | 0.07× | — | ||
| Q3 25 | 0.07× | — | ||
| Q2 25 | 0.13× | — | ||
| Q1 25 | 0.20× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 0.29× | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $117.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $113.6M | $161.8M |
| 自由现金流率自由现金流/营收 | 29.4% | 21.0% |
| 资本支出强度资本支出/营收 | 0.9% | 2.6% |
| 现金转化率经营现金流/净利润 | 2.33× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $461.1M | $509.4M |
8季度趋势，按日历期对齐
经营现金流PCTYRVTY
| Q4 25 | $117.0M | $182.0M | ||
| Q3 25 | $86.5M | $138.5M | ||
| Q2 25 | $86.6M | $134.3M | ||
| Q1 25 | $186.0M | $128.2M | ||
| Q4 24 | $54.2M | $174.2M | ||
| Q3 24 | $91.5M | $147.9M | ||
| Q2 24 | $79.9M | $158.6M | ||
| Q1 24 | $167.5M | $147.6M |
自由现金流PCTYRVTY
| Q4 25 | $113.6M | $161.8M | ||
| Q3 25 | $82.7M | $120.0M | ||
| Q2 25 | $81.1M | $115.5M | ||
| Q1 25 | $183.7M | $112.2M | ||
| Q4 24 | $51.2M | $149.8M | ||
| Q3 24 | $89.1M | $125.6M | ||
| Q2 24 | $73.6M | $136.6M | ||
| Q1 24 | $162.0M | $129.7M |
自由现金流率PCTYRVTY
| Q4 25 | 29.4% | 21.0% | ||
| Q3 25 | 21.8% | 17.2% | ||
| Q2 25 | 21.9% | 16.0% | ||
| Q1 25 | 43.6% | 16.9% | ||
| Q4 24 | 14.7% | 20.5% | ||
| Q3 24 | 26.8% | 18.4% | ||
| Q2 24 | 22.7% | 19.7% | ||
| Q1 24 | 44.2% | 20.0% |
资本支出强度PCTYRVTY
| Q4 25 | 0.9% | 2.6% | ||
| Q3 25 | 1.0% | 2.6% | ||
| Q2 25 | 1.5% | 2.6% | ||
| Q1 25 | 0.5% | 2.4% | ||
| Q4 24 | 0.9% | 3.4% | ||
| Q3 24 | 0.7% | 3.3% | ||
| Q2 24 | 1.9% | 3.2% | ||
| Q1 24 | 1.5% | 2.7% |
现金转化率PCTYRVTY
| Q4 25 | 2.33× | 1.85× | ||
| Q3 25 | 1.80× | 2.97× | ||
| Q2 25 | 1.78× | 2.49× | ||
| Q1 25 | 2.03× | 3.03× | ||
| Q4 24 | 1.45× | 1.84× | ||
| Q3 24 | 1.84× | 1.57× | ||
| Q2 24 | 1.64× | 2.87× | ||
| Q1 24 | 1.96× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PCTY
| Recurring Fees | $370.1M | 96% |
| Implementation Services And Other | $16.9M | 4% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
